Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2025-12-26 @ 4:06 AM
Study NCT ID:
NCT07027618
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-06-18
First Post:
2025-06-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
AI-Driven Personalization of End-of-Life Care for the Elderly
Sponsor:
Baqiyatallah Medical Sciences University
Organization:
Study Overview
Official Title:
"Evaluating the Effectiveness of an AI-Based Software in Personalizing High-Quality End-of-Life Care for the Elderly: A Randomized Controlled Clinical Trial"
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PEACE-AI
Brief Summary:
This study aims to evaluate the effectiveness of an artificial intelligence (AI)-based software in personalizing high-quality end-of-life care for elderly patients. As the elderly population grows, providing tailored and quality care during the final stages of life becomes increasingly important. This AI software continuously monitors vital signs and behaviors through wearable sensors, offers smart medication reminders, alerts the care team to potential risks, and provides personalized care plans along with psychological and social support.
The study is designed as a randomized controlled trial comparing two groups: one receiving standard end-of-life care and the other using the AI software. Key outcomes include improving quality of life, reducing adverse events like falls and emergency hospitalizations, increasing patient and family satisfaction, improving medication management, and reducing caregiver burden. Data will be collected over six months to assess these effects. The results will help determine whether AI technology can enhance end-of-life care for seniors and support families and healthcare providers.
The study is designed as a randomized controlled trial comparing two groups: one receiving standard end-of-life care and the other using the AI software. Key outcomes include improving quality of life, reducing adverse events like falls and emergency hospitalizations, increasing patient and family satisfaction, improving medication management, and reducing caregiver burden. Data will be collected over six months to assess these effects. The results will help determine whether AI technology can enhance end-of-life care for seniors and support families and healthcare providers.
Detailed Description:
This section provides a comprehensive overview of the study design, objectives, population, interventions, and methods without repeating information already included in other sections of the record. It elaborates on the rationale for using AI-based software to personalize end-of-life care for elderly patients, details the randomized controlled trial setup, explains inclusion and exclusion criteria, intervention specifics, outcome measures, data collection methods, and planned statistical analyses. This description ensures a clear understanding of the study's scope and methodology.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: